Pasithea Therapeutics Corp. (NASDAQ: KTTA) completed enrollment and initial dosing of three subjects in the first cohort of its Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE